The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 18, 2018
Filed:
Jun. 15, 2017
Applicant:
The Regents of the University of California, Oakland, CA (US);
Inventor:
Michael W. DeGregorio, Granite Bay, CA (US);
Assignee:
The Regents of the University of California, Oakland, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/035 (2006.01); A61K 31/085 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 31/055 (2006.01); A61K 31/09 (2006.01); A61K 31/137 (2006.01); A61K 31/138 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/353 (2006.01); A61K 31/5377 (2006.01); A61K 31/5415 (2006.01); A61K 33/24 (2006.01);
U.S. Cl.
CPC ...
A61K 31/035 (2013.01); A61K 31/055 (2013.01); A61K 31/085 (2013.01); A61K 31/09 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01); A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 31/353 (2013.01); A61K 31/5377 (2013.01); A61K 31/5415 (2013.01); A61K 33/24 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C12N 2760/16134 (2013.01);
Abstract
The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (TRIP) compound with an effective amount of the therapeutic agent. In particular embodiments, the TRIP compound enhances the immune response of the subject to the therapeutic agent. In some embodiments, the TRIP compound is administered in different dosing schedules to provide a biphasic immunomodulation effect.